SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001709401-22-000019
Filing Date
2022-11-09
Accepted
2022-11-09 08:01:46
Documents
60
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ruby-20220930.htm   iXBRL 10-Q 1650524
2 EX-31.1 exhibit311certification1.htm EX-31.1 19949
3 EX-31.2 exhibit312certification1.htm EX-31.2 19861
4 EX-32.1 exhibit321certification1.htm EX-32.1 6673
5 EX-32.2 exhibit322certification1.htm EX-32.2 6662
  Complete submission text file 0001709401-22-000019.txt   5576026

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ruby-20220930.xsd EX-101.SCH 31882
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ruby-20220930_cal.xml EX-101.CAL 46846
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ruby-20220930_def.xml EX-101.DEF 155284
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ruby-20220930_lab.xml EX-101.LAB 428146
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ruby-20220930_pre.xml EX-101.PRE 287233
54 EXTRACTED XBRL INSTANCE DOCUMENT ruby-20220930_htm.xml XML 675939
Mailing Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET, SUITE 300 CAMBRIDGE MA 02139 617-679-9600
Rubius Therapeutics, Inc. (Filer) CIK: 0001709401 (see all company filings)

IRS No.: 042688109 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38586 | Film No.: 221370727
SIC: 2836 Biological Products, (No Diagnostic Substances)